Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Verastem Inc
(NQ:
VSTM
)
3.820
-0.170 (-4.26%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Verastem Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
November 06, 2024
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
October 31, 2024
From
Verastem Oncology
Via
Business Wire
Verastem Oncology to Participate in Upcoming Investor Conferences
October 31, 2024
From
Verastem Oncology
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
October 17, 2024
Via
Benzinga
Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting
October 17, 2024
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting
October 09, 2024
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 07, 2024
From
Verastem Oncology
Via
Business Wire
Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference
September 10, 2024
From
Verastem Oncology
Via
Business Wire
Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting
September 10, 2024
From
Verastem Oncology
Via
Business Wire
Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024
September 03, 2024
From
Verastem Oncology
Via
Business Wire
VSTM Stock Earnings: Verastem Beats EPS, Beats Revenue for Q2 2024
August 09, 2024
VSTM stock results show that Verastem beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates
August 08, 2024
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer
July 29, 2024
From
Verastem Oncology
Via
Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
July 24, 2024
It's time to dive into the biggest pre-market stock movers for Wednesday as we check out all of the hottest news to start the day with!
Via
InvestorPlace
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
July 24, 2024
Via
Benzinga
Why Enphase Energy Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
July 24, 2024
Via
Benzinga
Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants
July 23, 2024
From
Verastem Oncology
Via
Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Verastem, Helios, and LegalZoom and Encourages Investors to Contact the Firm
July 23, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants
July 23, 2024
From
Verastem Oncology
Via
Business Wire
Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
July 12, 2024
Via
Benzinga
Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics
July 12, 2024
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 08, 2024
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Addition to Russell 3000® and Russell Microcap® Indexes
July 01, 2024
From
Verastem Oncology
Via
Business Wire
VERASTEM ALERT: Bragar Eagel & Squire, P.C. is Investigating Verastem, Inc. on Behalf of Verastem Stockholders and Encourages Investors to Contact the Firm
June 10, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Verastem, Inc. (VSTM)
June 07, 2024
From
Kirby McInerney LLP
Via
Business Wire
7 F-Rated Stocks to Avoid at All Costs in June
June 06, 2024
The stock market is doing well this year, so it would be a tragedy to own F-rated stocks. Here are some key stocks to avoid in June.
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's Intraday Session
May 27, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
May 27, 2024
Via
Benzinga
Crude Oil Rises 1%; Verastem Shares Slide
May 24, 2024
Via
Benzinga
Exposures
Fossil Fuels
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
May 24, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.